Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection

AIDS

Volumn 18, Issue 2, 2004, Pages 331-334

  Angel, Jonathan B ^a   Hu, Yu Wen ^b   Kravcik, Stephen ^a   Tsui, Rose ^c,d   Lee, Kok H ^e   Barbour, Jason ^c,e   Balaskas, Evan ^b   Branson, Bernard M ^f   Delwart, Eric L ^c,d   Grant, Robert M ^c,e  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Blood Centers of the Pacific   (United States)

^e GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; LAMIVUDINE; NELFINAVIR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SUPERINFECTION; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MUTATION; SEQUENCE ANALYSIS; SEXUAL PARTNERS; SUPERINFECTION; VIRAL LOAD;

EID: 10744221914     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401230-00027     Document Type: Article

References (16)

1. Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: Current state of knowledge and potential clinical consequences. Clin Infect Dis 2002; 34:1108-1114.
2. Angel JB, Kravick S, Balaskas E, Yen P, Badley AD, Camerron DW, et al. Documentation of HIV superinfection and acceleration of disease progression. In: 7th conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 2000 [Abstract LB2].
3. Kuiken CL, de Jong JJ, Baan E, Keulen W, Tersmette M, Goudsmit J. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992; 66:4622-4627.
4. Delwart E, Sheppard H, Walker B, Goudsmit J, Mullins J. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994; 68:6672-6683.
5. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-10502.
6. Lyles CM, Dorrucci M, Vlahov D, Pezzotti P, Angarano G, Sinicco A, et al. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis 1999; 180:1018-1024.
7. Obrien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:155-161.
8. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. AIDS 2000; 14:123-131.
9. Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, Promadej N, et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two infection drug users. J Virol 2002; 76:7444-7452.
10. Koelsch K, Smith D, Little S, Ignacio C, Macaranas T, Liegh Brown A, et al. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003; 17:F11-F16.
11. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al. HIV-1 superinfection despite broad CD8(+) T-cell responses containing replication of the primary virus. Nature 2002; 420:434-439.
12. Jost S, Bernard M, Kaiser L, Yerly S, Hirschel B, Samri A, et al. A patient with HIV-1 Superinfection. N Engl J Med 2002; 347:731-736.
13. Daar E, Frost S, Wong J, Hellmann N, Wrin T, Petropoulos C, et al. Mixed infection with multidrug resistant and wild type HIV strains in primary infection: Early rebound suggests loss of immune control. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 2002 [Abstract 96].
14. Otten R, Ellenberger D, Adams DR, Fridlund CA, Jackson E, Pieniazek D, Rayfield MA. Identification of a window period for susceptibility to Dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis 1999; 180:673-684.
15. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-2106.
16. Stranford SA, Ong JC, Martinez-Marino B, Busch M, Hecht FM, Kahn J, et al. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci U S A 2001; 98:597-602.